Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!

In Vivo Models for Assessing the Immunogenicity of Novel AAV Capsids and Transgenes

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

In Vivo Models for Assessing the Immunogenicity of Novel AAV Capsids and Transgenes

In Vivo Models for AAV Capsid and Transgene Immunogenicity

CELL & GENE | RNA | BIOLOGICS

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

Assessing the immunogenicity of Adeno-Associated Virus (AAV) vectors is a primary objective of any IND-enabling toxicology program. Both the viral capsid and the therapeutic transgene can elicit innate and adaptive immune responses, potentially limiting efficacy and raising safety concerns. A tailored preclinical strategy, using immunologically relevant in vivo models, is required to characterize these responses and generate the data package necessary for regulatory submission. This approach moves programs from candidate to IND within an 18-24 month timeline.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions

    What is the primary immunogenicity risk for AAV vectors?

    The principal risks involve pre-existing neutralizing antibodies (NAbs) against the AAV capsid, which can block transduction, and the development of cytotoxic T-lymphocyte (CTL) responses against either capsid proteins or the expressed transgene product, which can eliminate transduced cells.

    How is the appropriate in vivo model selected?

    Model selection is driven by the scientific question. Key factors include the immunological similarity to humans, the permissiveness of the model to the specific AAV serotype (e.g., AAV8, AAV9, or engineered capsids), and the overall objectives of the IND-enabling toxicology study.

    What are key endpoints in an AAV immunogenicity study?

    Core endpoints include NAb titers, T-cell activation assays (ELISpot, ICS), systemic and local cytokine profiling, and evaluation of transgene expression durability. These are supported by a full suite of histology and non-target tissue biodistribution assessments.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Characterizing Capsid and Transgene Immune Responses

The immune response to AAV vectors is a dual challenge. An initial innate immune response can be triggered upon administration, followed by a more specific and durable adaptive immune response targeting either the vector capsid or the novel transgene product. Designing studies to dissect these pathways is fundamental to minimizing clinical risk.

A tailored, science-based preclinical testing template is developed for each asset. We do not use a standardized approach. Our strategy is informed by decades of research into vector biology, including methods to modulate host factors to improve and sustain transgene expression (PMID: 15771962).

Selecting Translationally Relevant In Vivo Models

The predictive value of a preclinical program depends entirely on the selection of an appropriate animal model. The goal is to choose a species with an immune system that closely mirrors the human response to a given AAV vector. This requires a deep understanding of species-specific biological factors that can influence outcomes, such as the presence of unique protein variants that may alter function or immunogenicity (PMID: 21628398).

For many AAV programs, nonhuman primate (NHP) models provide the highest translational fidelity. Our >100,000 sq ft GxP-compliant facility is equipped for complex NHP studies, enabling accelerated study initiation to support demanding program timelines.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Featured Video: Engineering and Profiling AAV Capsids

This clip from our recent webinar discusses the key factors involved in AAV vector design and preclinical safety profiling.

A Data-Driven Path to IND Submission

Our scientific team functions as an embedded extension of your own, providing the high-fidelity in vivo intelligence for complex modalities required to advance your program. This approach has supported a 100% successful IND submission rate for programs initiated since 2019, with the Franklin Biolabs brand formally launching in 2024 to expand upon this legacy.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Animal Welfare and Program Oversight

Franklin Biolabs is committed to strict compliance with all applicable international, federal, and local regulations that govern the care and use of lab animals in biomedical research. We adhere to the 3Rs Principle (Replacement, Reduction, and Refinement) and provide enhanced housing with cognitive and social enrichment programs throughout the in-life phase of every study.

Technical Visualization: AAV Innate vs. Adaptive Immune Response

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities